Evaluation of an unconventional cancer treatment (the Di Bella multitherapy): results of phase II trials in Italy
BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7178.224 (Published 23 January 1999) Cite this as: BMJ 1999;318:224Data supplement
Members of the Italian Study Group for the Di Bella Multitherapy Trials
Table 3 Treatment status and survival (as of 31 October 1998; follow up 3-8 months) of patients receiving Di Bella multitherapy
Trial*
Living Dead (n=219)
Lost to follow up (n=22)
Total (n=386)
Receiving treatment (n=16) Not receiving treatment (n=129) Lymphoma 4 10 17 1 32 Lymphoid leukaemia 3 9 9 1 22 Breast cancer: Less severe 2 14 16 1 33 More severe 0 12 20 2 34 Lung cancer: Treated 0 19 40 6 65 Untreated 4 24 20 3 51 Colorectal cancer 1 10 18 5 34 Pancreatic cancer 1 9 17 2 29 Head and neck cancer 1 8 23 0 32 Glioblastoma 0 7 13 0 20 Advanced neoplasms 0 7 26 1 34 Total 16 129 219 22 386 %( 95% CI) 4.1 (2.4 to 6.6) 33.4 (28.7 to 38.4) 56.7 (51.6 to 61.7) 5.7 (3.6 to 8.5) 100.0 *See footnote to table 1.
Members of the Italian Study Group for the Di Bella Multitherapy Trials
Editorial committee
R Raschetti (Istituto Superiore di Sanità, Roma);
P Bruzzi (Istituto Nazionale Ricerca sul Cancro, Genoa);
D Greco, M Maggini, F Menniti-Ippolito, S Spila-Alegiani, G Traversa, G Benagiano (Istituto Superiore di Sanità, Rome).
Research coordinating centre
D Greco, R Raschetti (coordinators, Istituto Superiore di Sanità, Rome);
B Caffari, F Chiarotti, R Da Cas, B De Mei, G Di Giovambattista, M Maggini, F Menniti-Ippolito, S Modigliani, P Popoli, P Ruggeri, S Spila-Alegiani, C Tomino, G Traversa (Istituto Superiore di Sanità, Rome);
P Bruzzi (Istituto Nazionale Ricerca sul Cancro, Genoa);
T Gamucci (Istituto Regina Elena, Rome).
Steering committee
G Benagiano (chairman, Rome),
D Amadori (principal investigator, Forlì),
P Bruzzi (Genoa),
E Buiatti (Bologna),
E Ciranni (Rome),
F Cognetti (principal investigator, Rome),
G Colucci (principal investigator, Bari),
PF Conte (principal investigator, Pisa),
G Di Bella* (Modena),
D Greco (Rome),
S Iacobelli (principal investigator, Chieti),
F Mandelli (principal investigator, Rome),
E Marubini (Milan),
M Massotti (Rome),
S Monfardini (principal investigator, Naples),
F Oleari (Rome),
R Raschetti (Rome),
GL Sannazzari (principal investigator, Turin),
L Tomatis (Trieste),
U Veronesi (principal investigator, Milan).
*Dr G Di Bella, the son of Dr L Di Bella, participated at only the first two meetings of the Steering Committee. On many occasions, he strongly disagreed with the performance and results of the trials. No part of the present article has been discussed or agreed with Dr G Di Bella.
Participating centres
Ancona: R Cellerino (head), S Antognoli, R Berardi, R Bracci, P Lippe, F Pulita.
Aosta: F Di Vito (head), D Martinod, M Musi.
Aviano: A Veronesi (head), R Lazzarini.
Bari: G Colucci (principal investigator), V Attolico, F Giotta, M Longo, E Maiello.
Bologna: S Tura (head), F Gherlinzoni, M Tani.
Bolzano: H Amor (head), P Borona, F Girardi, C Graiff.
Cagliari: G Broccia (head), MG Corona, A Desogus, V Mascia, S Pasqualucci.
Catania: G Failla (head) MR Aiello, S Cordio, P Finocchiaro.
Chieti:S Iacobelli (principal investigator), E Melena, M De Tursi, MT Scognamiglio, N Tinari.
Forlì: D Amadori (principal investigator), M Maltoni, O Nanni, F Scardovi, P.Serra.
Genoa: R Rosso (head), F Boccardo, A Barp, T Coli, M Grimaldi.
Milan: N Cascinelli (head), L Ascani, E. Bajetta, P Bidoli, A Cassata, D De Candis, W Giannessi, G Procopio.
Milano: S Di Donato (head), A Boiardi, D Cerri, M Eoli, A Silvani.
Milan: U Veronesi (principal investigator), M Colleoni, N Rotmensz.
Naples: S Monfardini (principal investigator), G Comella, A De Matteis, A Gravina, C Gridelli, F Perrone, MR Salzano, C Sandomenico.
Naples: C Battista (head), G Iodice (Head), R Fico, A Nicchia.
Padua: M Lise (head), GL De Salvo, E. Di Lenardo, G Iadicicco.
Palermo: B Agostara (head), I Cafarelli.
Perugia: M Tonato (head), F Radicchi, S. Sorbolini, O Taschini.
Pisa: PF Conte (principal investigator), A Carmignani, L Del Mastro, A Gennari, C Orlandini.
Potenza: L Manzione (head), A Dinota (head), G Lombardi.
ReggioCalabria: G Gasparini (head), MG Arena, M Fanelli, F Modafferi, A Morabito. Rome: F Mandelli (principal investigator), P Fazi, F Mauro, M Martelli, C.Ricci, M Vignetti. Rome: F Cognetti (principal investigator), A D’Alessio, T Gamucci, D Giannarelli, E Magnani, P Rellecati, EM Ruggeri, M Zeuli.
Turin: GL Sannazzari (principal investigator), M Borgognone, R Chiò, A Gasco, R Ragona, M Sacco, R Soffietti, R Verna, M Tessa.
Turin: A Pileri (head).
Trento: E Galligioni (head), A Lucenti, F Moltrer, F Paolazzi.
Independent end point evaluation committee
AR Bianco (Naples),
R Labianca (Bergamo),
PL Rossi Ferrini (Florence),
G Simonetti (Rome),
A Sobrero (Udine).
Related articles
- This Week In The BMJ Published: 23 January 1999; BMJ 318 doi:10.1136/bmj.318.7178.0c
- Editorial Published: 23 January 1999; BMJ 318 doi:10.1136/bmj.318.7178.208
- MULTIMEDIA Published: 23 January 1999; BMJ 318 doi:10.1136/bmj.318.7178.268a
- Letter Published: 17 April 1999; BMJ 318 doi:10.1136/bmj.318.7190.1073
See more
- Breast cancer: Inaction on inequalities has led to unequal progress, say expertsBMJ April 16, 2024, 385 q854; DOI: https://doi.org/10.1136/bmj.q854
- Cancer: Fast tracked drugs often do not improve clinical outcomes, say researchersBMJ April 08, 2024, 385 q818; DOI: https://doi.org/10.1136/bmj.q818
- NHS rolls out fast tracked immunotherapy for advanced endometrial cancerBMJ March 05, 2024, 384 q557; DOI: https://doi.org/10.1136/bmj.q557
- Teledentistry may help in detecting oral cancers in current GP and dentist shortagesBMJ March 01, 2024, 384 q512; DOI: https://doi.org/10.1136/bmj.q512
- UK’s progress on cancer survival has slowed in past decade, figures showBMJ February 02, 2024, 384 q290; DOI: https://doi.org/10.1136/bmj.q290